GRT-001
/ Granite Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 16, 2026
GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).
(clinicaltrialsregister.eu)
- P1 | N=40 | Not yet recruiting | Sponsor: Granite Bio AG
New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 1
Of
1
Go to page
1